The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany
No abstract is available for this item.
Volume (Year): 11 (2010)
Issue (Month): 3 (June)
|Contact details of provider:|| Web page: http://www.springer.com|
|Order Information:||Web: http://www.springer.com/medicine/health+informatics/journal/10198/PS2|
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Paul Grootendorst & David Stewart, 2006. "A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 735-742.
- Schneeweiss, Sebastian & Maclure, Malcolm & Walker, Alexander M. & Grootendorst, Paul & Soumerai, Stephen B., 2001. "On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective," Health Policy, Elsevier, vol. 55(2), pages 97-109, February.
- Paul V. Grootendorst & John K. Marshall & Anne M. Holbrook & Lisa R. Dolovich & Bernie J. O'Brien & Adrian R. Levy, 2004. "The Impact of Differential Cost Sharing of Non-Steroidal Anti-Inflammatory Agents on the Use and Costs of Analgesic Drugs," Social and Economic Dimensions of an Aging Population Research Papers 115, McMaster University.